Clinical and research priorities for combined modality therapy in stage III NSCLC [0.03%]
III期非小细胞肺癌多学科综合治疗的临床和研究优先事项
Angela Lin,Andrea Bezjak
Angela Lin
Stage III NSCLC comprises of a heterogeneous group of patients with regard to stage, extent of disease and prognosis. Disease presentation can often be complex in clinical practice, and the challenges are not well-defined in clinical trials...
Liesbeth Lemmens
Liesbeth Lemmens
Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel h...
Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature [0.03%]
不可切除的伴有N3淋巴结的寡转移性肺癌的治愈性治疗：病例报告及文献回顾
Vanita Noronha,Amit Joshi,Vijay M Patil et al.
Vanita Noronha et al.
Untreated NSCLC patients with brain metastases have a median survival of approximately 2 months; locally advanced stage III NSCLC patients treated with chemoradiation have a median survival of 16-19 months. Select patients with oligometasta...
Case Reports
Lung cancer management. 2016 Apr;5(1):21-27. DOI:10.2217/lmt-2016-0002 2016
Community hospital experience using electromagnetic navigation bronchoscopy system integrating tidal volume computed tomography mapping [0.03%]
社区医院使用集成潮气量CT映射的电磁导航支气管镜系统的经验
Abhijit A Raval,Leah Amir
Abhijit A Raval
Results of the first 50 consecutive patients referred for bronchoscopy or surgery by the tumor review board to confirm suspect lung lesions identified by computed tomography. Electromagnetic navigation was used to biopsy peripheral pulmonar...
Hirva Mamdani,Shadia I Jalal
Hirva Mamdani
Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer [0.03%]
神经酪氨酸激酶基因融合：肺癌靶向治疗的另一机遇
Luis E Raez,Christian Rolfo
Luis E Raez